Skip to main content
13 August 2026
12 November 2025

Brenntag Signs Exclusive Distribution Deal with ArcticZymes for Bioprocessing Enzymes

Brenntag, the global market leader in chemicals and ingredients distribution, announced a new and exclusive distribution agreement with ArcticZymes AS on the salt-active nucleases: SAN HQ, SAN-HQ GMP, M-SAN HQ, M-SAN HQ GMP, developed for the efficient removal of nucleic acids in gene therapy, vaccine production and o…

12 November 2025

Complete Genomics and SOPHiA GENETICS Partner to Advance Global Precision Oncology

Complete Genomics, a leading innovator in genomic sequencing, announced a collaboration with SOPHiA GENETICS, a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform. The companies aim to broaden …

07 November 2025

NEXT Oncology Enters Japanese Market with Kansai Medical University Collaboration

NEXT Oncology, an Avacare business, has expanded its services to Asia through a strategic partnership with Kansai Medical University in Osaka, Japan.  Under the guidance of Dr. Toshio Shimizu as the Director of the Phase I program, Kansai Medical University will now offer patients in Japan the opportunity to participa…

06 November 2025

Ailux and Eli Lilly Partner to Advance AI-Driven Bispecific Antibody Discovery

Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi, a global leader in AI drug discovery,  announced a strategic platform-based collaboration with Eli Lilly and Company ("Lilly") to accelerate the discovery and development of bispecific antibodies for the treatment of various diseases.…

05 November 2025

Raffles Medical, Gene Solutions Partner to Enhance Precision Oncology Research

Singapore-based Raffles Medical Group and Gene Solutions, headquartered in Vietnam, have signed a Memorandum of Understanding (MoU) to streamline patient recruitment for oncology clinical trials, marking a significant milestone in advancing precision medicine in Southeast Asia. Under this partnership, the Raffles Med…

03 November 2025

Novartis Completes Acquisition of Tourmaline Bio to Advance Cardiovascular Innovation

Novartis announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. With the completion of the acquisition, shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline, have ceased trading on the Nasdaq Stock Market LLC and Tourmaline is now an indirect wholly owned subs…

Page 23 of 36